Effect of tofisopam on the single-oral-dose pharmacokinetics and pharmacodynamics of the cyp3a4 probe drug alprazolam.
Drabant
Sándor
S
Tóth
Mária
M
Bereczki
Andrea
A
Bajnógel
Judit
J
Tömlö
Judit
J
Klebovich
Imre
I
D000284:Administration, Oral; D000525:Alprazolam / Q000008:administration & dosage* / Q000097:blood / Q000493:pharmacokinetics* / Q000494:pharmacology; D014151:Anti-Anxiety Agents / Q000008:administration & dosage* / Q000097:blood / Q000493:pharmacokinetics* / Q000494:pharmacology; D000928:Antidepressive Agents / Q000008:administration & dosage / Q000494:pharmacology*; D019540:Area Under Curve; D001569:Benzodiazepines / Q000008:administration & dosage / Q000494:pharmacology*; D051544:Cytochrome P-450 CYP3A; D065607:Cytochrome P-450 Enzyme Inhibitors; D003577:Cytochrome P-450 Enzyme System / Q000378:metabolism*; D004347:Drug Interactions; D006801:Humans; D008099:Liver / Q000187:drug effects / Q000201:enzymology; D008297:Male
D014151:Anti-Anxiety Agents; D000928:Antidepressive Agents; D065607:Cytochrome P-450 Enzyme Inhibitors; D001569:Benzodiazepines; D003577:Cytochrome P-450 Enzyme System; D051544:Cytochrome P-450 CYP3A; C510163:CYP3A4 protein, human; C012582:tofisopam; D000525:Alprazolam